IRulya Therapeutics Inc. Common Stock
IRLA
66 hedge funds and large institutions have $26M invested in IRulya Therapeutics Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 31 closing their positions.
54% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $727K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17.32% less ownership
Funds ownership: 56.13% → 38.82% (-17%)
20% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 25
22% less funds holding
Funds holding: 85 → 66 (-19)
58% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 31
74% less capital invested
Capital invested by funds: $99.5M → $26M (-$73.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$987K |
| 2 |
Millennium Management
New York
|
+$987K |
| 3 |
ECM
Evolution Capital Management
Crystal Bay,
Nevada
|
+$626K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$602K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$15.4M |
| 2 |
BlackRock
New York
|
-$3.2M |
| 3 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$2.84M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.64M |
| 5 |
SC
Sculptor Capital
New York
|
-$1.39M |
IRLA Hedge Fund Activity: Q2 2022 in Review
66 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q2 2022, worth a combined $26M — down 74% from $99.5M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of IRLA and 13 opened new positions — a net loss of 18 holders — while 25 trimmed existing stakes and 20 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $987K. The largest seller was Capital World Investors, exiting entirely with an estimated $15.4M sold.
- 66 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q2 2022, down from 85 in Q1 2022.
- Funds reported $26M of IRulya Therapeutics Inc. Common Stock stock for Q2 2022, down 74% quarter-over-quarter.
- 13 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q2 2022 and 31 closed out, a net change of -18 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $987K added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q2 2022 was Capital World Investors, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2022.